BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 9441781)

  • 1. An evaluation of prognostic factors in uterine carcinosarcoma.
    Nordal RR; Kristensen GB; Stenwig AE; Nesland JM; Pettersen EO; Trope CG
    Gynecol Oncol; 1997 Dec; 67(3):316-21. PubMed ID: 9441781
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The prognostic significance of stage, tumor size, cellular atypia and DNA ploidy in uterine leiomyosarcoma.
    Nordal RR; Kristensen GB; Kaern J; Stenwig AE; Pettersen EO; Tropé CG
    Acta Oncol; 1995; 34(6):797-802. PubMed ID: 7576748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Leiomyosarcoma of the uterus: A clinicopathologic, DNA flow cytometric, p53, and mdm-2 analysis of 49 cases.
    Blom R; Guerrieri C; Stâl O; Malmström H; Simonsen E
    Gynecol Oncol; 1998 Jan; 68(1):54-61. PubMed ID: 9454661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Malignant mixed Müllerian tumors of the uterus: a clinicopathologic, DNA flow cytometric, p53, and mdm-2 analysis of 44 cases.
    Blom R; Guerrieri C; Stâl O; Malmström H; Sullivan S; Simonsen E
    Gynecol Oncol; 1998 Jan; 68(1):18-24. PubMed ID: 9454654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The prognostic significance of surgery, tumor size, malignancy grade, menopausal status, and DNA ploidy in endometrial stromal sarcoma.
    Nordal RR; Kristensen GB; Kaern J; Stenwig AE; Pettersen EO; Tropé CG
    Gynecol Oncol; 1996 Aug; 62(2):254-9. PubMed ID: 8751558
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Uterine carcinosarcoma and high-risk endometrial carcinomas: a clinicopathological comparison.
    Zhang C; Hu W; Jia N; Li Q; Hua K; Tao X; Wang L; Feng W
    Int J Gynecol Cancer; 2015 May; 25(4):629-36. PubMed ID: 25633654
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Significance of histologic pattern of carcinoma and sarcoma components on survival outcomes of uterine carcinosarcoma.
    Matsuo K; Takazawa Y; Ross MS; Elishaev E; Podzielinski I; Yunokawa M; Sheridan TB; Bush SH; Klobocista MM; Blake EA; Takano T; Matsuzaki S; Baba T; Satoh S; Shida M; Nishikawa T; Ikeda Y; Adachi S; Yokoyama T; Takekuma M; Fujiwara K; Hazama Y; Kadogami D; Moffitt MN; Takeuchi S; Nishimura M; Iwasaki K; Ushioda N; Johnson MS; Yoshida M; Hakam A; Li SW; Richmond AM; Machida H; Mhawech-Fauceglia P; Ueda Y; Yoshino K; Yamaguchi K; Oishi T; Kajiwara H; Hasegawa K; Yasuda M; Kawana K; Suda K; Miyake TM; Moriya T; Yuba Y; Morgan T; Fukagawa T; Wakatsuki A; Sugiyama T; Pejovic T; Nagano T; Shimoya K; Andoh M; Shiki Y; Enomoto T; Sasaki T; Fujiwara K; Mikami M; Shimada M; Konishi I; Kimura T; Post MD; Shahzad MM; Im DD; Yoshida H; Omatsu K; Ueland FR; Kelley JL; Karabakhtsian RG; Roman LD
    Ann Oncol; 2016 Jul; 27(7):1257-66. PubMed ID: 27052653
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic parameters in carcinosarcomas of the uterus: a clinico-pathologic study.
    Bodner-Adler B; Bodner K; Obermair A; Czerwenka K; Petru E; Leodolter S; Mayerhofer K
    Anticancer Res; 2001; 21(4B):3069-74. PubMed ID: 11712812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Flow cytometric analysis of uterine sarcoma: ploidy and S-phase rate as prognostic indicators.
    Malmström H; Schmidt H; Persson PG; Carstensen J; Nordenskjöld B; Simonsen E
    Gynecol Oncol; 1992 Feb; 44(2):172-7. PubMed ID: 1544595
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A multivariate analysis of clinicopathologic factors for predicting outcome in uterine sarcomas.
    Wolfson AH; Wolfson DJ; Sittler SY; Breton L; Markoe AM; Schwade JG; Houdek PV; Averette HE; Sevin BU; Penalver M
    Gynecol Oncol; 1994 Jan; 52(1):56-62. PubMed ID: 8307502
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic significance of DNA ploidy in patients with stage II and stage III colon carcinoma: a prospective flow cytometric study.
    Lanza G; Gafà R; Santini A; Maestri I; Dubini A; Gilli G; Cavazzini L
    Cancer; 1998 Jan; 82(1):49-59. PubMed ID: 9428479
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic factors in uterine carcinosarcoma: a clinicopathologic study of 25 patients.
    Iwasa Y; Haga H; Konishi I; Kobashi Y; Higuchi K; Katsuyama E; Minamiguchi S; Yamabe H
    Cancer; 1998 Feb; 82(3):512-9. PubMed ID: 9452269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stage III uterine carcinosarcoma: 2009 International Federation of Gynecology and Obstetrics Staging System and Prognostic Determinants.
    Garg G; Kruger M; Christensen C; Deppe G; Toy EP
    Int J Gynecol Cancer; 2011 Dec; 21(9):1606-12. PubMed ID: 21720252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic parameters for survival of patients with malignant mesenchymal tumors of the uterus.
    Nola M; Babić D; Ilić J; Marusić M; Uzarević B; Petrovecki M; Sabioncello A; Kovac D; Jukić S
    Cancer; 1996 Dec; 78(12):2543-50. PubMed ID: 8952563
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The prognostic relevance of histological type in uterine sarcomas: a Cooperation Task Force (CTF) multivariate analysis of 249 cases.
    Gadducci A; Sartori E; Landoni F; Zola P; Maggino T; Cosio S; Tisi G; Lissoni A; Ferrero AM; Cristofani R
    Eur J Gynaecol Oncol; 2002; 23(4):295-9. PubMed ID: 12214727
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterizing sarcoma dominance pattern in uterine carcinosarcoma: Homologous versus heterologous element.
    Matsuo K; Takazawa Y; Ross MS; Elishaev E; Yunokawa M; Sheridan TB; Bush SH; Klobocista MM; Blake EA; Takano T; Baba T; Satoh S; Shida M; Ikeda Y; Adachi S; Yokoyama T; Takekuma M; Yanai S; Takeuchi S; Nishimura M; Iwasaki K; Johnson MS; Yoshida M; Hakam A; Machida H; Mhawech-Fauceglia P; Ueda Y; Yoshino K; Kajiwara H; Hasegawa K; Yasuda M; Miyake TM; Moriya T; Yuba Y; Morgan T; Fukagawa T; Pejovic T; Nagano T; Sasaki T; Richmond AM; Post MD; Shahzad MMK; Im DD; Yoshida H; Omatsu K; Ueland FR; Kelley JL; Karabakhtsian RG; Roman LD
    Surg Oncol; 2018 Sep; 27(3):433-440. PubMed ID: 30217299
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical outcomes of uterine carcinosarcoma: results of 94 patients.
    Gokce ZK; Turan T; Karalok A; Tasci T; Ureyen I; Ozkaya E; Kose MF; Tulunay G
    Int J Gynecol Cancer; 2015 Feb; 25(2):279-87. PubMed ID: 25611900
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of DNA cytometry in 281 premenopausal patients with lymph node negative breast carcinoma randomized in a control trial: multivariate analysis with Ki-67 index, mitotic count, and microvessel density.
    Mandard AM; Denoux Y; Herlin P; Duigou F; van De Vijver MJ; Clahsen PC; van Den Broek L; Sahmoud TM; Henry-Amar M; van De Velde CJ
    Cancer; 2000 Oct; 89(8):1748-57. PubMed ID: 11042570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective analysis of DNA ploidy, proliferative index and epidermal growth factor receptor as prognostic factors for pretreated uterine cancer.
    Nagai N; Oshita T; Fujii T; Kioka H; Katsube Y; Ohama K
    Oncol Rep; 2000; 7(3):551-9. PubMed ID: 10767367
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of DNA ploidy and proliferation in 309 colorectal carcinomas as determined by two-color multiparametric DNA flow cytometry.
    Zarbo RJ; Nakhleh RE; Brown RD; Kubus JJ; Ma CK; Mackowiak P
    Cancer; 1997 Jun; 79(11):2073-86. PubMed ID: 9179053
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.